Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA Meetings, Conferences and Workshops

FDA Meetings, Conferences and Workshops

                        FDA Meetings, Conferences, and Workshops: Past Events
          FDA Annual Reports on Conferences


                        Public Calendar - Meetings With FDA Officials Home
          News & Events
          FDA Meetings, Conferences and Workshops
          Model Informed Drug Development Approaches for Immunogenicity Assessments - 06/09/2021 - 06/09/2021FDA Meetings, Conferences and Workshops Public
    Event Title
              Model Informed Drug Development Approaches for Immunogenicity Assessments


                  June 9, 2021

  

    
  Share
    Post
    Linkedin

    Email
    PrintOn This Page
      Meeting Information
                Event MaterialsDate:
          
  


     
           

June 9, 2021

 

  The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), in collaboration with the Center for Drug Evaluation and Research (CDER), are announcing the following public workshop entitled “Model Informed Drug Development Approaches for Immunogenicity Assessments.”

PURPOSE OF THE PUBLIC WORKSHOP:

The purpose of this public workshop is to discuss best practices and future directions of quantitative methods for predicting immunogenicity of biologic products. This public workshop is also being conducted to satisfy one of FDA's performance goals included in the sixth reauthorization of the Prescription Drug User Fee Amendments (PDUFA VI), part of the FDA Reauthorization Act of 2017 (FDARA), to hold a series of workshops related to model-informed drug development (MIDD).

BACKGROUND:

Under FDARA, and in accordance with section I, part J of the PDUFA VI Performance Goals, FDA agreed to convene a series of workshops to identify best practices for MIDD (https://www.fda.gov/media/99140/download, see page 27).  Each workshop focuses on current and emerging scientific approaches, including methodological limitations.  The workshop announced in this notice fulfills FDA’s performance commitment under PDUFA VI, specifically for modeling immunogenicity and correlates of protection for evaluating biological products, including vaccines and blood products.

TOPICS FOR DISCUSSION:

Topics for discussion include the following:

Current *in silico* methodologies used to assess drug immunogenicity;
	Available data resources and data needs for MIDD approaches to evaluate immunogenicity at various stages of drug development;
	Possible applications and limitations of MIDD approaches for desired immunogenicity of vaccine/allergenic products; and
	Insight into the possible future applications of MIDD and good modeling practicesModel Informed Drug Development Approaches for Immunogenicity Assessments Agenda

LECTURE VIDEOS:



Opening Remarks
	Peter Marks, MD. PhD. – Welcome Remarks
	Rajanikanth Madabushi, PhD. – Integration of MIDD into Drug Development and Regulatory Decision-MakingSession 1
	Aleksander Popel, PhD. – Quantitative Systems Pharmacology: Applications to Immuno-Oncology
	Xiaoying, Chen, PhD. – A Systems Pharmacology Modeling Approach to Immunogenicity Prediction
	Andrzej Kierzek, PhD. – Quantitative Systems Pharmacology to Predicting and Managing Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins
	Lora Hamuro, PhD. – Quantitative Assessment of the Immunogenicity Impact on Safety and Efficacy for a Nivolumab & Ipilimumab Combination in 1L MelanomaSession 2
	Atul Butte, MD, PhD. – Translating a Trillion Points of Data into Therapies, Diagnostics, and New Insights into Immunological Disease
	Malachi Griffith, PhD. – Bioinformatics and Immunogenomics Approaches for Neoantigen Target Identification
	Morten Nielsen, PhD. – The Use of HLA Class II Antigen Presentation Prediction in the Context of Immunogenicity Assessment of Biologics
	Brandon Dekosky, PhD. – Exploring Personalization of Human Immune Responses with High-Throughput Immune Receptor Data

Session 3
	Yongqun He, Ph.D. – COVID-19 Vaccine Machine Learning, Ontology Modeling, and Cov19VaxKB
	Peter Gilbert, PhD. – Learning Immune Correlates of Protection from Vaccine Efficacy Trials
	Richard White, PhD. and Sophie Rhodes, Ph.D – Using Epidemiological and Immunostimulation/Immunodynamic Modelling to Estimate TB Vaccine Impact and Optimise Vaccine Dose
	Ryoko Sawamura, PhD. – QSP Application to COVID-19 Vaccine Clinical Development

Session 4
	Guangping Gao, PhD. – Vector-Related Immunogenicity as a Potential Roadblock to AAV Gene Therapy - Assessment and Mitigation
	Nirjal Bhattarai, PhD. – Immunogenicity of Chimeric Antigen Receptor T Cells
	Jochem Gokemeijer, PhD. – Pre-Clinical Immunogenicity Risk Assessment Tools and Strategies for Novel Modalities

LOCATION:

The public workshop will be held virtually via Adobe Connect. Webcast information will be provided upon completion of registration.

REGISTRATION:

OMB Control No. 0910-0429

Expiration Date: 5/31/2023

Paperwork Reduction Act Statement:  According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a valid OMB control number.  The valid OMB control number for this information is 0910-0429 and the expiration date is 5/31/2023.  The time required to complete this information collection is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestion for reducing burden to PRAStaff@fda.hhs.gov.

To register for this public workshop, please visit the following website:  https://www.eventbrite.com/e/model-informed-drug-development-approaches-for-immunogenicity-assessments-tickets-138618787525.

TRANSCRIPTS:

Please be advised that as soon as a transcript of the public workshop is available, it will be accessible at https://www.regulations.gov.  It may be viewed at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. A link to the transcript will be available on the internet at https://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/default.htm.

QUESTIONS:

Please submit any questions you may have during the workshop to: MIDDWorkshop@fda.hhs.gov

FOR FURTHER INFORMATION CONTACT:

Loni Warren Henderson or Sherri Revell, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 1118, Silver Spring, MD 20993, 240-402-8010, CBERPublicEvents@fda.hhs.gov (subject line: MIDD Workshop).





Event Materials

  Title
            File Type/SizeModel Informed Drug Development Approaches for Immunogenicity Assessments Agenda
              pdf               (180.06 KB)

                                                                                  Content current as of:
      09/22/2021
         
                   
Regulated Product(s)
		 BiologicsMore Meetings,
      Conferences, and
      Workshops
        
        FDA Meetings, Conferences and Workshops

          
                        FDA Meetings, Conferences, and Workshops: Past Events
          FDA Annual Reports on Conferences


                        Public Calendar - Meetings With FDA Officials
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop